Jefferies Downgrades Adagene(ADAG.US) to Hold Rating, Cuts Target Price to $3.5
Jefferies Downgrades Adagene to Hold From Buy, Price Target Is $3.50
Adagene Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
H.C. Wainwright Maintains Adagene(ADAG.US) With Buy Rating, Maintains Target Price $5
Buy Rating Affirmed on Adagene: Promising ADG126 Clinical Data and Market Underappreciation
Morgan Stanley Reaffirms Their Buy Rating on Adagene (ADAG)
H.C. Wainwright Maintains Adagene(ADAG.US) With Buy Rating, Maintains Target Price $5
Adagene Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Adagene Analyst Ratings
Analysts Offer Insights on Healthcare Companies: EFFECTOR Therapeutics (EFTR), Adagene (ADAG) and Aquestive Therapeutics (AQST)
Analysts Conflicted on These Healthcare Names: Abbott Labs (ABT), Adagene (ADAG) and Teleflex (TFX)
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Adagene Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Adagene Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Oncternal Therapeutics (ONCT), Adagene (ADAG) and Omega Therapeutics (OMGA)
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
No Data
No Data